A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

NCT Number	NCT07623369
Lead Sponsor	Huahui Health Collaborators: BeOne Medicines
Conditions	Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Endometrial Cancer, Cervical Cancer +4 more
Enrollment	56 participants
Start Date	2026-06
Primary Completion	2028-08 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-03